Wouter Laroy
Hoofd Techniek/Wetenschap/O&O bij MyCartis NV
Oorsprong van het eerstegraads netwerk van Wouter Laroy
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
MyCartis NV
MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium.
11
| Holding Company | Biotechnology | 11 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Wouter Laroy via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Pacira CryoTech, Inc.
Pacira CryoTech, Inc. Medical/Nursing ServicesHealth Services Pacira Cryotech, Inc. develops novel technologies for treatment of peripheral nerves. Its iovera treatment harnesses the power of cold with the Focused Cold Therapy delivery system and delivers immediate results for both therapeutic and aesthetic applications. The firm’s iovera treatment does not use toxins, chemicals, or pharmaceuticals to achieve results and leaves nothing behind in the body. The company was founded by Lisa Elkins in 2005 and is headquartered in Fremont, CA. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
MDXHEALTH SA | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
BMEYE BV
BMEYE BV Electronic Equipment/InstrumentsElectronic Technology BMEYE BV operates as a non-invasive cardiovascular monitoring company. The firm manufactures and distributes non-invasive technology, hemodynamic monitoring equipment and related medical devices. It offers finger arterial pressure and cardiac output technologies. The company was founded in April 2005 and is headquartered in Amsterdam, the Netherlands. | Electronic Equipment/Instruments | Director/Board Member | |
Coöperatief LSP IV UA | Investment Managers | Director/Board Member | |
GIMV NV | Investment Managers | Director/Board Member | |
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Private Equity Investor | |
Korys Management NV
Korys Management NV Investment ManagersFinance Korys Management NV is a Private Equity/Venture Capital firm, a subsidiary of Korys NV founded in 2000. Korys Management NV is headquartered in Halle. | Investment Managers | Private Equity Analyst | |
ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Participatiemaatschappij Vlaanderen NV
Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Investment Managers | Private Equity Investor Private Equity Investor | |
deVGen NV
deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director of Finance/CFO | |
ABLYNX | Biotechnology | Director/Board Member Director/Board Member | |
Erasmus University Rotterdam | College/University | Doctorate Degree | |
University of Utrecht | College/University | Graduate Degree | |
Ghent University | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree | |
Katholieke Universiteit Leuven | College/University | Graduate Degree Graduate Degree | |
Licensing Executives Society | Corporate Officer/Principal | ||
MERUS N.V. | Biotechnology | Director/Board Member | |
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
CELYAD ONCOLOGY SA | Biotechnology | Chairman Director/Board Member | |
ARGENX SE | Pharmaceuticals: Other | Director/Board Member | |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Pharmaceuticals: Major | Director/Board Member | |
FlandersBio vzw
FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Semaia Pharmaceuticals | Chief Executive Officer | ||
Biocartis SA
Biocartis SA Medical SpecialtiesHealth Technology Biocartis SA develops molecular diagnostic solutions. It focuses on Oncology. The firm’s products include Idylla and Oncology assays and mutation tests. It also provides instant access to personalized medicine for patients. The company was founded by Rudi Pauwels in 2007 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member Chief Executive Officer | |
Université d'Aix-Marseille | College/University | Graduate Degree | |
JenaValve Technology, Inc.
JenaValve Technology, Inc. Medical SpecialtiesHealth Technology JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE. | Medical Specialties | Director/Board Member Director/Board Member | |
Valiance Advisors LLP
Valiance Advisors LLP Investment ManagersFinance Valiance Advisors LLP is the alternative asset management subsidiary of Valiance Asset Management Ltd. in Great Britain. The firm was founded by Jan Pensaert in 2008. Headquartered in London, Valiance Advisors manages Life Sciences portfolio for individual and institutional investors. | Investment Managers | Chief Executive Officer | |
Valiance Asset Management Ltd.
Valiance Asset Management Ltd. Financial ConglomeratesFinance Valiance Asset Management Ltd. provides investment services. It offers sovereign funds, pension funds, leading families and individuals investment services. The company was founded by Jan Pensaert in 2008 and is headquartered in St. Peter Port, Guernsey. | Financial Conglomerates | Chief Executive Officer | |
Chemsyn Science Laboratories | Sales & Marketing | ||
BIOTALYS NV | Chemicals: Agricultural | Director/Board Member Director/Board Member | |
SPARK THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
Microphyt SA
Microphyt SA BiotechnologyHealth Technology Microphyt SA researches, develops, produces and markets natural bioactive products from microalgae. Its solutions are intended to address the needs of personal-care, food and health-care industries worldwide, through a differentiated and sustainable approach and proprietary technologies allow controlled and industrial-scale supply of microalgae biomass and extracts. The firm''s Industrial scale photo bioreactors developed and patented and are designed to produce specific strains of microalgae by preserving cell integrity and yielding commercial quantities of slow-growing or biofilm-forming species. The company was founded by Arnaud Muller-Feuga in 2007 and is headquartered in Baillargues, France. | Biotechnology | Director/Board Member | |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member | |
BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Chairman Chief Executive Officer | |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Chairman Director/Board Member | |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Director/Board Member | |
Onward Medical SA
Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Biotechnology | Director/Board Member | |
Xylocor Therapeutics, Inc.
Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Director/Board Member | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member | |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Antelope Dx BV
Antelope Dx BV Packaged SoftwareTechnology Services Antelope Dx BV develops a point-of-need diagnostics platform that provides patients, consumers, and healthcare professionals with on-the-spot access to key health parameters. The private company is based in Ghent, Belgium. The Belgian company was founded in 2019 by Jan-Willem Hoste and Hilde Windels. Hilde Windels has been the CEO since 2019. | Packaged Software | Director/Board Member Founder | |
Xilis, Inc.
Xilis, Inc. Medical SpecialtiesHealth Technology Xilis, Inc. engages in the development of droplet-based microfluidics technology devices for precision cancer diagnostics and drug development. It offers Xilis platform. The company was founded by Xiling Shen and David Shu and is headquartered in Durham, NC. | Medical Specialties | Director/Board Member | |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
ONWARD MEDICAL N.V. | Miscellaneous Commercial Services | Director/Board Member | |
EQT Life Sciences Group BV
EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor | |
PHAXIAM THERAPEUTICS S.A. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
België | 19 |
Nederland | 14 |
Verenigde Staten | 12 |
Frankrijk | 4 |
Zwitserland | 3 |
Sectoraal
Health Technology | 27 |
Finance | 9 |
Consumer Services | 6 |
Commercial Services | 4 |
Electronic Technology | 3 |
Operationeel
Director/Board Member | 122 |
Chief Executive Officer | 18 |
Corporate Officer/Principal | 15 |
Chairman | 14 |
Independent Dir/Board Member | 12 |
Sterkste connecties
Insiders | |
---|---|
Rudi Mariën | 31 |
Roald Borré | 25 |
John Berriman | 24 |
John Paul de Koning | 21 |
Hilde Windels | 18 |
Christoph Waer | 16 |
Chris de Jonghe | 15 |
Jan Pensaert | 13 |
Carol Greve-Philips | 8 |
Griet Vanpoucke | 7 |
Mieke van Acker | 1 |
- Beurs
- Insiders
- Wouter Laroy
- Bedrijfsconnecties